Human papillomavirus (HPV) testing is used in primary cervical screening, as an 2 adjunct to cervical cytology for the management of low grade abnormal cytology, 3 and in a test of cure. PapilloCheck® (Greiner Bio-One) is a PCR-based DNA microarray 4 system that can individually identify 24 HPV types, including the 13 high risk (HR 
Introduction 24
Organised cervical screening by cytology has been effective at reducing cervical 25 cancer incidence and mortality in countries where resources permit (1). The 26 established role of persistent high risk human papillomavirus (HPV) infection in 27 cervical carcinogenesis (2-4) has led to the use of HPV testing alongside cytology to 28 triage minor cytological abnormalities, in post-treatment follow up and, more 29 recently, as the primary screen of cervical samples (5). The rationale for this lies in 30 the added sensitivity and high negative predictive value of HPV testing compared 31 with cervical cytology (6). Until recently, the only HPV test approved for use in 32 cervical screening programmes was the Hybrid Capture-2 (HC2) assay (Qiagen), 33 which employs an RNA cocktail probe to induce a chemiluminescent reaction upon 34 HPV DNA binding with any of 13 high risk types. HC2 generally has good clinical 35 utility for the detection of high grade premalignant disease of the cervix (cervical 36 intraepithelial neoplasia (CIN)2 or 3) (7, 8), but there have been concerns about its 37 low specificity and positive predictive value (PPV). Several reports have indicated 38 that it erroneously detects low risk HPV types (9-11) and may even cross react with 39 4 PapilloCheck® (Greiner Bio-One) is a PCR-based DNA microarray system that 46 identifies 24 HPV types individually, including the 13 HR types detected by HC2. The 47 "PapilloCheck® high-risk" assay now available detects 14 HR types -those as for HC2 127 plus HPV66. Thus the addition of HPV type 66 has also been assessed separately and 128 all other types detected by PapilloCheck® (6, 11, 40, 42, 43, 44, 53, 70, 73, 82) some 129 of which are considered "probably high risk" have been referred hereafter as "low 130 risk" types. 131 132
Roche prototype Reverse Line Blot and Roche Linear Array assays 133
Either one of these Roche assays (collectively referred to as "RLB" hereafter) were 134 performed on all LBC samples that tested positive for HPV by HC2 or PapilloCheck®. 135
These genotyping assays amplify 37 HPV types simultaneously, including the 13 HC2 136 target types, using PGMY09-PGMY11 (PGMY09/11) L1 consensus primer PCR. The 137 assays were carried out according to the manufacturer's instructions except that an 138 automated rather than the manual AmpliLute Liquid Extraction Kit (Roche) for DNA 139 extraction was used. DNA was extracted from a 50μl aliquot of the stored cell pellet 140 using the automated Roche MagNA Pure LCextraction system in conjunction with the 141 Total Nucleic Acid Extraction kit (Roche). The purified total nucleic acid was eluted 142 with a low-salt buffer to a final volume of 100μl. This automated system was 143 validated and certified by Roche Molecular Diagnostics using HPV test panels before 144 any testing was carried out on clinical material. 145
146

Statistical analysis 147
The clinical performance of PapilloCheck® relative to HC2 was determined according 148 to its ability to detect underlying CIN2+ by calculating relative sensitivities and 149 specificities with 95% confidence intervals. A power calculation indicated that a 150 Table 2 shows the sensitivity of each assay for detecting CIN2+ in women with 211 abnormal cytology, stratified by age and cytology result. Sensitivity was consistently 212 higher at younger ages and for more severe cytology, and HC2 was consistently more 213 sensitive than HR PapilloCheck®; overall the sensitivity for detecting CIN2+ was 214 93.5% for HC2 and 89.0% for HR PapilloCheck®, giving PapilloCheck® a relative 215 sensitivity of 0.95 (95% CI: 0.93 -0.97, p<0.0001). HR PapilloCheck® missed a total of 216 34 CIN2+ lesions that were positive by HC2 and HC2 missed 4 CIN2+ lesions that 217 were positive by PapilloCheck®. The proportion testing negative by both HC2 and 218
PapilloCheck® was 6.0% (40/672) overall. This proportion was much higher for CIN2+ 219 than for CIN3+, and was higher in the first 6 months of the trial (CIN2+ 21.3% 220 (17/80); CIN3+ 2.7% (2/75)) than later (CIN2 6.8% (16/234); CIN3+ 1.8% (5/283)). Table 3 shows the specificity of the tests based on women without CIN2+ diagnoses 224 by age and cytology in the prospectively collected samples. Overall, PapilloCheck® 225 was significantly more specific than HC2 (92.4% vs 88.2% respectively; p<0.0001), 226
giving a relative specificity of 1.05 (95% CI: 1.04-1.06). The specificity decreased with 227 increasing severity of cytological abnormality and remained higher for PapilloCheck®. UK than the prevalence in previous rounds. Overall, the specificity of the 294
PapilloCheck® assay was 92.4% compared to 88.2% with HC2, giving a relative 295 specificity of 1.05 (95% CI: 1.04-1.06). The specificity of the PapilloCheck® assay was 296 significantly higher than HC2 for women with borderline or mild cytology, implying 297 that PapilloCheck® could also be used as a triage test following cytology. 298 299 HC2 is a highly sensitive test for detecting CIN2+, but the relatively low specificity 300 leads to high referral rates, particularly in populations with higher HPV prevalence 301 such as young women or those with abnormal cytology. HR HPV DNA was not 302 detected by PapilloCheck® or RLB in 32.0% (1008/3146) of the HC2+ samples ( Table 4 shows much higher CIN2+ rates among HC2+ women who were also positive 311
by PapilloCheck® (1.9% (27/1412) in normal cytology and 32.2% (145/451) in 312 abnormal cytology) compared to those who were negative by PapilloCheck® (0.4% 313 (5/1190) in normal cytology and 6.5% (6/93) in abnormal cytology). The relative 314 sensitivity for CIN3+ was 95% (95% CI: 93%-98%) in all women where HC2 missed 315 11/358 (3.1%) CIN3+ cases and PapilloCheck® missed 27/358 (7.5%) CIN3+ cases. 316
Eleven of these 27 cases missed by PapilloCheck® were positive for HPV18 or HPV45 317
by RLB, another 6 were positive for other HR types, leaving 11 that had either low 318 risk types (n=6 all HC2+) or no detectable HPV infection (n=5 all HC2-). Meijer (17) 319
states that an acceptable alternative test to HC2 should have a relative sensitivity for 320 CIN2+ of no less than 90% in women aged over 30 years. PapilloCheck® fulfils this 321 criterion with a relative sensitivity of 94% (95% CI: 91%-97%) in this age group (Table  322 2). PapilloCheck® is therefore a suitable alternative to HC2 for primary cervical 323 screening, alongside Abbott M2000, Roche Cobas, Hologic Cervista and Gen-Probe 324
APTIMA HR HPV tests (19). 325 326
This is the largest study to date that has compared the clinical performance of 327 studies have included an analysis of baseline samples from women participating in 329 the POBASCAM trial, where 1,665 cervical cytology specimens, including 192 from 330 women with CIN2+ were tested with both PapilloCheck® and the GP5+/6+ PCR-331 enzyme immunoassay. They found that the two HPV testing methods performed 332 similarly in terms of CIN2+ detection (20) . A population-based study of 878 cervical 333 cytology specimens, in which there were 32 underlying CIN2+ lesions, also found 334 good correlation between PapilloCheck®, HC2 and the the GP5+/6+ PCR-enzyme 335 immunoassay (21). Another study tested a colposcopy-referral population of 239 336 women of whom 93 had CIN2+ using PapilloCheck® and the linear array assay, and 337 found a high overall concordance rate between the two assays (22). 338
339
We conducted parallel retrospective and prospective analyses of ARTISTIC (6) 340 cervical cytology samples in this study. Using ARTISTIC samples had the benefit that 341 the samples were well characterised in terms of clinical follow up data. The 342 advantage of the retrospective analysis was that we were able to enrich our sample 343 set for underlying CIN2+ lesions, which in turn gave sufficient power to the study to 344 allow a meaningful comparison of HC2 versus PapilloCheck® for the detection of 345 CIN2+. Agreement between PapilloCheck® and the Roche line blot assays remained 346 good despite the samples having been processed, frozen and stored for up to six 347 years before they were tested with PapilloCheck®. In the prospective analysis we 348 were able to compare the performance of the two tests contemporaneously under 349 the same conditions using fresh cervical cytology material, but there were only 18 350 underlying CIN2+ lesions. A prospective study sufficiently large to detect small 351 differences in the performance characteristics of these tests would be extremely 352 expensive and is unlikely to be performed. 353
354
Greiner Bio-One has developed a microarray-based test kit using the same 355 technology as the approved PapilloCheck® which detects the 14 carcinogenic types 356 (Greiner Bio-One, REF 505060). This is important because any HPV test used in 357 primary cervical screening must detect high risk HPV rather than low risk types or a 358 mixture of the two and we have shown that PapilloCheck® (considering these 14 HR 359 types) is significantly more specific than HC2 with only a small decrease in sensitivity. 360
Compared with the HC2 test, which using the Qiagen QiaSymphony and Rapid 361
Capture is capable of processing and testing 88 samples in 9 hours, the PapilloCheck® 362 method employed in this study required 1.5 days to process and test 80 samples. 363
Greiner Bio-One has now developed an automated platform which is expected to 364 launch in early 2016, and which will be capable of a throughput and ergonomic 365 performance comparable with HC2. We and others have shown that PapilloCheck® 366 also compares well with other PCR based systems such as the Roche Linear Array, 367 and this genotyping capability will have clinical utility for stratifying HPV positive 368 women, especially as vaccinated cohorts come through to cervical screening. In 369 conclusion, this large study has confirmed that the PapilloCheck® high-risk would be 370 a suitable HPV assay in primary screening, providing sufficient sensitivity and 371 improved specificity relative to HC2. 
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